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Abstract
Introduction
In an African setting surgery is generally accepted as the treatment of first choice for glau-
coma. A problem with trabeculectomy surgery for the glaucomas is the frequent co-exis-
tence and exacerbation of cataract. We report a randomized controlled trial to compare the
use of beta radiation with 5FU in combined cataract and glaucoma surgery.
Participants and Methods
Consenting adults aged >40 years with glaucoma, an IOP>21mmHG and cataract were
enrolled and randomised to receive either 1000cG β radiation application or sub-conjuncti-
val 5fluorouracil (5FU) at the time of combined trabeculectomy and phaco-emulsification
with lens implant surgery.
Results
385 individuals were eligible for inclusion of whom 301 consented to inclusion in the study
(one eye per patient). 150 were randomised to the 5FU arm and 151 received β radiation.
In the 12 months following surgery there were 40 failures (IOP>21mmHg) in the 5FU arm
and 34 failures in the beta arm. The hazard ratio for the beta radiation arm compared to
the 5FU arm, adjusted for IOP at baseline, was 0.83 (95% c.i. 0.54 to 1.28; P = 0.40). The
improvement from mean presenting visual acuities of 0.91 and 0.86 logMAR to 0.62 and
0.54 in the 5FU and beta arms respectively was comparable between groups (P = 0.4
adjusting for baseline VA). Incidence of complications did not differ between the two
groups.
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Discussion
This study highlights several important issues in the quest for a therapeutic strategy for the
glaucomas in an African context. Firstly, there is no evidence of an important difference
between the use of 5FU and beta radiation as an anti-metabolite in phacotrabeculectomy.
Secondly phacotrabeculectomy is a successful operation that improves visual acuity as well
as controlling IOP in a majority of patients. Although the success of trabeculectomy in lower-
ing IOP is reduced when combined with phacoemulsification compared with trabeculectomy
alone, this finding has to be set against the possible need for subsequent cataract surgery fol-
lowing trabeculectomy alone, which represents a second trip and expense for the patient and
results in 10–61% failure of the trabeculectomy at one year post-cataract surgery.
Trial Registration
ISRCTN Registry ISRCTN36436933
Introduction
In 2010 285 million people in the world were estimated to be visually impaired, with 39 million of
those blind [1]. More than 80% of these visually impaired individuals live in low and middle
income countries, with 15% in Africa. This continent has only 12% of the world’s population and
the population is relatively young. Two recent large population based surveys in Nigeria and
Kenya identified the glaucomas as the second most common cause of blindness after cataract [2,3].
Like cataract there are treatments for the glaucomas, but unlike cataract there is not an oper-
ation that returns sight to the blind. Glaucomas have been called the ‘thief of sight’ because the
disease is not noticed until major visual loss has occurred. Loss of sight is irreversible and thus
treatment is preventive not curative.
The principal treatment approach for the glaucomas is to lower the pressure in the eye with
a view to preventing further optic nerve damage. This can be achieved by use of regular topical
or systemic medication, laser treatment or surgery. In an African setting surgery is generally
accepted as the treatment of first choice[4]. The most common surgical procedure is trabecu-
lectomy surgery. However, in African patients a successful outcome of glaucoma surgery is
often compromised by an aggressive healing response[5,6].For this reason anti-metabolites
may be used, most commonly 5 fluorouracil (5FU) or mitomycin C (MMC)[7]
Beta-radiation has features that make it suitable for use in glaucoma surgery. Application is
rapid and simple: both the dose and the area treated can be controlled with accuracy. Further-
more, the beta-radiation delivery device, once purchased, is self-sterilising and has a long work-
ing life (20 years+) with minimal maintenance required. In settings where a regular supply of
drugs and maintenance of equipment are not assured, this makes beta-radiation particularly
attractive. Four randomised controlled trials of β-radiation in trabeculectomy have been pub-
lished. These show that use of beta-radiation with trabeculectomy surgery results in a lower
risk of surgical failure compared to trabeculectomy surgery alone. A Cochrane review con-
cluded that a trial of beta radiation versus anti-metabolites is warranted [8].
At present, prevention of blindness from the glaucomas faces several challenges in low and
middle income settings. A major problem lies in getting those who present to eye departments
with the disease to accept treatment. Compliance with glaucoma surgery at our hospital (Com-
prehensive Community Based Rehabilitation and Training Hospital (CCBRT) in Dar-Es-
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Salaam, Tanzania) is only 48% [9]. Patients usually arrive blind in one eye and with severe dis-
ease in the other. They are extremely concerned when offered no hope for the blind eye and
surgery to their ‘good eye’. Furthermore the surgery does not improve vision but rather may
make vision temporarily worse in the longer term interest of preserving that vision. This out-
come of ‘vision saved’ rather than ‘vision restored’ is extremely difficult to present to and get
accepted by patients.
An additional problem with trabeculectomy surgery for the glaucomas is the frequent co-exis-
tence and exacerbation of cataract[10]. In an African context, if the cataract does not cause signif-
icant disability it would not normally warrant surgical intervention. Removal of the cataract
would, none-the-less, offer brighter vision and avoid the need for surgery at a later date. Offering
patients improved vision might make patients more willing to accept glaucoma surgery.
Despite extensive discussion of combined cataract and trabeculectomy surgery in the litera-
ture, there are remarkably few papers comparing trabeculectomy surgery and phacoemulsifica-
tion combined with trabeculectomy surgery alone (Table 1), and none are from the African
continent. One study in Japan reported considerably worse outcomes after combined surgery.
The other studies do not suggest a major difference between the two procedures. All studies
reported a deterioration in visual acuity 1 year after trabeculectomy alone. Unsurprisingly an
improvement in visual acuity was seen for those having the combined procedure.[11–14]
Table 1. Studies comparing trabeculectomy surgery alone with combined phacoemulsification and trabeculectomy surgery.
Ref
No.
Study Design N F/Up Results
11 • Long term effect on IOP of
Phacotrabeculectomy versus
trabeculectomy
• UK 2003
• Retrospective
Comparative
• 44 eyes 12
months
• Final mean IOP (mmHg)
• Phacotrabeculectomy = 15.5
• Trabeculectomy = 13.0 (P = 0.0017)
•Mean reduction in IOP
• Phacotrabeculectomy = 6.7
• Trabeculectomy = 11
• Vision gain in Phacotrabeculectomy
Vision loss in trabeculectomy
12 • Trabeculectomy with MMC and
Phacotrabeculectomy with MMC
• Japan 2013
• Prospective
Comparative
• Success criteria;
reduction in IOP
(mmHg)
• A: 21
• B: 18
• C  15
• 52 eyes
• 26:26 Phacotrabeculectomy/
trabeculectomy
1 year • Post operative success
• Trabeculectomy /
Phacotrabeculectomy;
• A: 96.2% / 72.9%
• B: 96.2% / 61.1%
• C: 80.4% / 46.2%
• Visual improvement in
Phacotrabeculectomy
13 • 5FU safety and efﬁcacy in
Trabeculectomy and
Phacotrabeculectomy
• Australia 2001
• Retrospective • 186 eyes
• 51/ 135 phacotrabeculectomy/
Trabeculectomy
• Success IOP<16 mmHg and
30% reduction ±Medication
2 years • Failure rate
• Phacotrabeculectomy 39%
• Trabeculectomy with 5FU 20%
• Trabeculectomy without 5FU 46%
• Visual improvement in
Phacotrabeculectomy signiﬁcant
14 • IOP outcome with
Phacotrabeculectomy-5FU and
Trabeculectomy-5FU
• UK 2006
• Retrospective
• Success
• IOP<16 mmHg
• IOP <20 ±medication
• 92 eyes
• 45 phacotrabeculectomy/
• 47 trabeculectomy
2 years •Mean IOP and(%)reduction:
• Phacotrabeculectomy 16.1 (31.2)
• Trabeculectomy 13.9 (44.6)
• IOP <16
• Phacotrabeculectomy (62.2%)
• Trabeculectomy (63.8%)
• IOP <20
• Phacotrabeculectomy (93.3%)
• Trabeculectomy (97.9%)
• Visual acuity
• Phacotrabeculectomy improved
(62%)
• Trabeculectomy worse (40%)
doi:10.1371/journal.pone.0161674.t001
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Current practice for combined surgery uses 5FU. However, this drug is known to cause cor-
neal epithelial toxicity and endothelial compromise if it inadvertently enters the anterior cham-
ber. In addition, use of this drug relies on a regular supply chain We undertook a retrospective
review of the outcome of 163 combined cataract and trabeculectomy with 5FU operations in
CCBRT Hospital. Of those seen at 6 months post operation, 16/19 (84% (95% c.i. 68–100%))
[15] had an IOP of 6-20mmHG compared to 90% (95% c.i. 85–95%) in a previous audit of tra-
beculectomy surgery alone[16]. 85% (95% c.i. 64–95%) had improved visual acuity following
the combined procedure
In order to further investigate the optimal management strategy for glaucoma therapy in an
African context we undertook a randomized controlled trial to compare the use of beta radia-
tion with 5FU in combined cataract and glaucoma surgery.
Participants and Methods
We performed a randomised controlled trial of combined phacoemulsification and trabeculect-
omy surgery using 1000cG β radiation application in one arm and 5 Fluorouracil in the other
at the CCBRT hospital in Tanzania. The study was, of necessity, open label in theatre. However,
the outcome assessor was not aware of participants’ treatment assignment. Black African
patients from the general ophthalmology clinic who met the referral criteria (Table 2) were
given appointments for the Phacotrabeculectomy research clinic where the trial ophthalmolo-
gist (KD) examined them to determine if they met the trial’s inclusion criteria (Table 2),
including assessing whether the cataract was sufficient to decrease vision and require surgical
interventionand the patient was expected to benefit from the phacotrabeculectomy procedure.
A cataract was considered to decrease vision and require surgical intervention if the affected
eye had a best corrected visual acuity Snellen’s 6/12 (logMAR 0.3010) and a LOCS (Lens
Opacities Grading System) III grade ofNC3, C4 or P3. Patients meeting the inclusion cri-
teria had the purpose of the study and the procedures involved explained, and those who
agreed to participate signed an informed consent form. Patients were frequently accompanied
by a close relative who was also involved in the decision-making process.
All enrolled patients underwent a detailed clinical assessment. Visual acuity, pin hole acuity
and best corrected visual acuity were measured using a reduced logarithm of minimum angle of
resolution acuity chart (log Mar) by an optometrist who had been trained to use the chart. The
tumbling E chart (log Mar) was used for unlettered patients. Intraocular pressure was measured
using a Goldmann tonometer which was calibrated and checked at the beginning of each clinic.
Three IOP readings were taken per patient at least 30 minutes apart. Patients who were on IOP
Table 2. Referral, Inclusion and Exclusion criteria.
Referral criteria Inclusion criteria Exclusion criteria
• IOP >21mmHg
• C/D ratio >0.8
• Age > 40 years
• Any form of
cataract
• Consent to inclusion and participation in trial.
• Changes in the optic disc characteristic of glaucoma. The presence of a focal
or diffuse area of optic disc rim loss, so that the neuroretinal rim tissue in any
quadrant is less than 5% of the disc diameter in that meridian. Extensive loss of
neuroretinal rim tissue with marked optic disc cupping giving a cup disc ratio
greater than 0.8.
• A measured intraocular pressure greater than 21 mmHg on at least one visit
before the time of listing for surgery as measured by Goldmann applanation
tonometry.
• An open angle on gonioscopy
• Cataract sufﬁcient to decrease vision and require surgical intervention.
• Unwillingness to participate in the study
• Anterior segment neovascularisation
• Past trauma to the eye or ocular adnexae
• Retinal or optic nerve neovascularisation
• Aphakia or pseudophakia
• Previous ocular surgery
• Uveitis
• Inability/unwillingness to give informed consent
• Unwillingness to accept randomization
• Pregnancy or female of childbearing age who may
be pregnant at the time of treatment (LMP)
• Long term use of topical or systemic steroids
doi:10.1371/journal.pone.0161674.t002
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lowering medication on referral were asked to stop the medication and to return after 2 weeks.
Gonioscopy was done using a 4 mirror gonio lens and modified Shaffer gradings were recorded
where a grade IV represents observation of the ciliary body; grade III indicates scleral spur; grade
II indicates anterior trabecular meshwork; grade I Schwalbe’s line visible and grade 0 Schwalbe’s
line not visible. Grade II and above was taken as open angle. Cataract was assessed after dilation
using the LOCS III grading system[17]. Prior to the start of the trial, staff were trained by an
external expert (JK) to minimize inter-observer variation for the key outcome variables of IOP
and visual acuity. Training exercises were performed to standardize LOCS grading of the cataract
and optic disc assessment. Visual field testing was not routinely performed. Phacotrabeculectomy
surgical technique was left to the operating surgeon’s discretion.
Randomization and masking
Patients were randomized to receive either β radiation or 5FU in blocks of 10 using computer
generated random numbers. The randomised allocation was printed and sealed in an opaque
envelope with the study number on the outside. The envelopes were kept in the theatre. The
trial ophthalmologist (KD) was masked to the randomisation group since he neither operated
on the patients nor attended the surgical sessions of the trial patients. The relevant sealed enve-
lope (matching the patient’s study number) was opened after the phacoemulsification proce-
dure by the surgeon’s assistant. At the completion of surgery the randomization slip was
returned to the envelope and kept in the custody of the research assistant (IK). The randomiza-
tion code was only known to IM, who was not involved in clinical care.
Intervention procedures
For patients in the β radiation arm, the β probe disc was placed over the surgical site after con-
junctival closure for sufficient time to administer 1000CGy. The radiation emitter contained
strontium-90/yttrium-90 in an 8 mm disc applicator (SI-20; Nycomed Amersham, Bucking-
hamshire). Strontium -90 decays to yttrium-90 on release of the particle. A Tanzanian National
Atomic Energy commission licence was obtained before using the probe and the licence
renewed every year. For patients receiving 5FU, surgeons decided if they wanted to place 5FU
soaked cotton pledgets under the bleb prior to trabeculectomy or give it as an injection subcon-
junctivally at the conclusion of surgery.
Follow up
All patients were seen at the trial clinic post-operatively by the trial ophthalmologist (KD). On
day 1 post-operatively they were all given a combination of dexamethasone and chlorampheni-
col eye drops for use four times a day for three months. Subsequent follow up examinations
were scheduled for day 5–7, 1 month, 3 months, 6 months and 12 months post operatively.
Log Mar visual acuities with and without pin hole correction were measured at all visits except
day 1. Refraction was done at 3 and 12 months, IOP was measured at all visits and after the
first day, IOP was measured twice with an interval between measurements of at least 30 min-
utes. A detailed postoperative assessment was done at each visit, which included bleb assess-
ment, anterior chamber activity and morphology, status of the posterior capsule and
fundoscopy. Any complications were noted and the operating surgeon was informed if any fur-
ther surgical intervention was needed. At the 12 month follow-up, IOP was measured three
times with at least a 30 minute interval between measurements and the bleb was assessed using
the Moorfields Bleb Grading system (Refer to www.blebs.net website). An ongoing record was
kept of subsequent reviews in the clinic.
Beta Radiation vs 5FU in Phacotrabeculectomy Surgery
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Outcomes
The primary outcome was surgical success at 12 months, defined as an intraocular pressure
less than 16mmHg without ocular hypotensive treatment. To aid comparability with other
studies in Africa, we also examined a definition of success as an IOP21 mmHG, with or with-
out ocular hypotensive treatment. Secondary outcomes were time to IOP failure, visual acuity,
and intra and postoperative complications.
Statistical analysis
Sample size. To detect a clinically important increase in the success proportion from 75%
to 90% with a power of 80% (5% significance level) we estimated that we required 113 patients
per arm. Allowing for losses to follow-up of up to 25%, we estimated that we would need to
enroll about 150 patients per arm (300 in total).
All data were recorded on trial proformas and double entered using EpiInfo v7.1.2.0 (http://
wwwn.cdc.gov/epiinfo/7/). The two files were cross checked and any discrepancies resolved by
reference to the original record. The data were then checked for consistency.
Analysis was undertaken using Stata version 14 (www.stata.com). The baseline characteristics
of the patients in each arm were examined to check that the two arms were comparable. The pro-
portions of patients with a successful outcome at each follow-up point were compared using the
chi-squared test. Cumulative risk of failure was estimated using the Kaplan-Meier method, and
the null hypothesis of no difference between the two arms was tested using the log rank test. Haz-
ard ratios and 95% confidence intervals were estimated using Cox regression. Generalised esti-
mating equations (GEE) with an identify link function was used to model the probability of
success across all of the observations, accounting for within individual correlation. Visual acuity
was analysed using linear regression. Proportions of patients experiencing complications were
compared using the chi-squared test. Two-sided statistical tests were used throughout.
Ethics
The study was approved by the Tanzanian research regulatory body, the National Institute for
Medical Research (NIMR) and registered as NIMR/HQ/R.8a/Vol. IX/717. All patients gave
free and informed written consent (signature or thumb print) prior to enrolment in the study.
Patient recruitment took place between 9th April 2009 and 18th October 2012. The trial was
registered with the ISRCT on 30th November 2009, ISRCTN36436933. The delay in commenc-
ing patient recruitment from the time ethical clearance was granted (4th August 2008) was
because of logistical challenges which included importation of radioactive material in to Tanza-
nia, inspection of the radioactive applicator by the Radiation control office, training of staff
handling and storing the applicator and putting the trial systems in place. A preoccupation
with these trial logistics also led to delay in registering the trial with the ISRCT. The trial
stopped enrolling patients once the sample size was achieved and the trial was closed once the
last patient enrolled completed the one year follow up assessment. The full trial protocol is
available on request from the Phacotrabeculectomy β-project research team through the corre-
sponding author. There are no ongoing trials at present.
Results
Overall, 301 of 385 eligible patients were randomised; 151 to the β radiation group (Fig 1). The
two treatment arms were similar with respect to socio-demographic, ophthalmic and surgical
factors at enrolment (Table 3). Attendance for follow-up at 10 plus months was not associated
Beta Radiation vs 5FU in Phacotrabeculectomy Surgery
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Fig 1. Flow diagram of recruitment and follow-up.
doi:10.1371/journal.pone.0161674.g001
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with age, gender, occupation or educational status. The most common cause for loss to follow-
up was moving address.
Primary outcome: surgical success
Table 4 shows the numbers of patients attending at the different follow up points throughout
the study period together with the success proportion for two outcomes (IOP<16 mmHg, not
on ocular hypotensive treatment; IOP21mmHg) and mean IOP. There was no suggestion of
a difference between the two arms at any time point except 6 months, when the proportion of
patients with IOPs>21mmHg was somewhat higher in the beta radiation arm (19% versus
8%; Chi2 = 4.79 P = 0.03) and at 12 months when the proportion of patients with IOP’s
16mmHg or on ocular hypotensive treatment was somewhat higher in the 5FU arm (59% vs
48%;Chi2 = 2.1 p = 0.15). Using GEE with an identify link function to model the probability of
Table 3. Baseline Personal, Ophthalmic and Surgical factors in the two treatment arms.
Variable β radiation group (N = 151) 5FU group (N = 150)
n (%) n (%)
Age (years)
<60 14 (9) 18 (12)
60–69 67 (44) 60 (40)
70+ 70 (46) 72 (48)
Sex
Male 104 (69) 103 (69)
Female 47 (31) 47 (31)
Education
None 59 (39) 58 (39)
Primary 69 (46) 67 (45)
Secondary and above 23 (15) 25 (17)
Family history of glaucoma
Yes 51 (34) 55 (37)
No 100 (66) 95 (63)
Glaucoma
POAG 129 (85) 133 (89)
PXF 22 (15) 17 (11)
Used ocular hypotensive treatment**
Yes 31 (21) 41 (28)
No 118 (79) 108 (73)
Mean presenting visual acuity (log Mar (95%CI))* 0.86 (0.76–0.96) 0.91 (0.80–1.01)
Mean presenting IOP (mmHg (95%CI)) 34.2 (32.8–35.7) 34.9 (33.4–36.3)
Mean vertical C/D ratio (95% CI) 0.83 (0.81–0.85) 0.82 (0.80–0.84)
Mean disc height (mm) (95%CI) 2.06 (2.02–2.10) 2.05 (2.01–2.10)
Mean presenting VA (log Mar (95%CI)) fellow eye* 1.45 (1.24–1.66) 1.45 (1.25–1.64)
* A logMar coding for Counting Fingers = 2, Hand Motion = 3, Light Perception = 4.
** Seventy three individuals (31 beta and 42 5FU) were on IOP lowering medication immediately before
surgery. The two principal drugs were topical betablockers (77%) and oral diamox (62%). 46 (79%) of the 58
on topical betablockers were taking it for less than 6 weeks preoperatively and only 4 had been on it for 1
year or more. All but 3 of the 45 on oral acetazolamide were taking it for less than two weeks pre-operatively.
doi:10.1371/journal.pone.0161674.t003
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success across all of the observations, accounting for within individual correlation, the proba-
bility of success at any time point was estimated to be 6.7 percentage points higher in the beta
arm than in the 5 Fluorouracil arm (95% c.i. -1.6% to +15.0%; P = 0.11).
To facilitate comparison with a majority of literature on trabeculectomy surgery, the
remaining analyses have been performed using an IOP cut-off of 21mmHg. Over the entire
period of follow-up a total of 104 (34.5%) cases of surgical failure were identified (mean intra-
ocular pressure> 21mmHg with or without ocular hypotensive treatment). The cumulative
incidence of failure was similar in the two arms (log rank test p = 0.37, Fig 2). Up to day 430
there were 43 failures identified in the 5FU arm and 35 in the beta arm. Cumulative success
proportions up to day 430 were 66% (95% c. i. 55% to 74%) and 72% (63% to 79%) respectively.
To exactly 12 months there were 40 failures (cumulative survival 70% (62% to 77%)) in the
5FU arm and 34 failures (cumulative survival 74% (65% to 80%)) in the beta arm. The hazard
ratio for the beta radiation arm compared to the 5FU arm, adjusted for IOP at baseline, was
0.83 (95% c.i. 0.54 to 1.28; P = 0.40).
If treatment success is defined as a reduction of 30% or more in IOP and an IOP21
mmHg, then at one year the proportion of cross-sectional successful outcomes in the 5FU and
beta radiation arms were 82.6% and 82.7% respectively (P = 0.99).
Secondary outcomes
Visual acuity. The mean visual acuity by arm at different time points is shown in Table 5.
The beta-radiation group consistently had slightly better acuities (of the order of 0.1 logMAR
from 1 month on), which could have been due to chance with the exception of Day 7, at which
point there was some evidence of better visual acuity in the beta radiation group.
Complications. The per-operative complications by randomisation group are shown in S1
Table. The post-operative complications are shown in Table 6. No evidence was found of them
being directly linked to subsequent surgical failure. A total of 49 (16.8%) patients had postoper-
ative bleb needling done: 28/150 (18.7%) in the 5FU group and 21/151 (14.0%) in the β group
Table 4. Surgical Success judged by two criteria IOP16, not on ocular hypotensive treatment and21mmHg at different follow up intervals.
Beta radiation 5 Fluorouracil Chi2p-
valueβ vs
5FU
<16mmHg
Follow up
interval
N Success
<16mmHg
and not on
treatment (%)
Success
21
mmHg (%)
Number on
treatment
Mean
IOP
(mmHg)
N Success<16mmHg
and not on treatment
(%)
Success
21
mmHg (%)
Number on
treatment
Mean
IOP
(mmHg)
1 month
(15–59
days)
134 95 (70.9%) 121
(90.3%)
2 13.5 141 91 (64.5%) 120
(85.1%)
0 14.8 0.26
3 months
(60–119
days)
109 75 (68.8%) 100
(91.7%)
3 14.6 110 68 (61.8%) 99 (90.0%) 2 15.2 0.28
6 months
(141–229
days)
97 62 (63.9%) 79 (81.4%) 1 16.1 100 58 (58.0%) 92 (92%) 3 15.6 0.40
12 months
(301–429
days)
75 39 (52.0%) 68 (90.6%) 4 15.8 86 35 (40.7%) 76 (88.4%) 3 16.5 0.15
Not seen at
1 year but
seen at > 1
year(>430
days)
27 11 (40.7%) 24 (88.8%) 1 17.2 23 10 (43.5%) 19 (82.6) 0 17.8 0.85
doi:10.1371/journal.pone.0161674.t004
Beta Radiation vs 5FU in Phacotrabeculectomy Surgery
PLOS ONE | DOI:10.1371/journal.pone.0161674 September 8, 2016 9 / 15
(p = 0.26). The proportion of those who underwent needling that subsequently failed were 59%
and 57% in the two treatment groups respectively.
Discussion
This is the first randomised controlled trial comparing β radiation and 5 Fluorouracil as
adjuncts in combined phacotrabeculectomy surgery. It is also the first large prospective study
of phacoemulsification combined with trabeculectomy in an African population.
Fig 2. Survival analysis of IOP control in combined trabeculectomy and cataract surgery. Failure is mean
IOP>21mmHg with or without medical treatment.
doi:10.1371/journal.pone.0161674.g002
Table 5. Mean Visual acuities (log Mar) at different follow up intervals in the two treatment arms.
Va (logMar) t-test p value (adjusting for
baseline VA)β 5fu
Day 7 (3–14 days) 0.90 (95% c.i. 0.78,
1.02)
1.12 (95% c.i. 0.99,
1.25)
0.02
1 month (15–59 days) 0.74 (95% c.i. 0.63,
0.85)
0.85 (95% c.i. 0.74,
0.96)
0.27
3 months (60–119
days)
0.64 (95% c.i. 0.52,
0.76)
0.74 (95% c.i. 0.62,
0.86)
0.25
6 months (141–229
days)
0.63 (95% c.i. 0.51,
0.76)
0.73 (95% c.i. 0.62,
0.85)
0.41
12 months(301–429
days)
0.54 (95% c.i. 0.39,
0.70)
0.63 (95% c.i. 0.51) 0.53
>1 year (>430 days) 0.63 (95% c.i. 0.43,
0.82)
0.73 (95% c.i. 0.41,
1.04)
0.40
doi:10.1371/journal.pone.0161674.t005
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Following the results of an earlier trial of trabeculectomy with beta radiation in South Africa
[18], our sample size calculation was based on detecting superiority of beta-radiation over 5FU,
which was the standard treatment at CCBRT when we initiated the trial. In a Cochrane review
similar effects of 5FU and mitomycin C (MMC) [19] were reported. A subsequent review, pub-
lished in 2014 suggested that mitomycin C may have a marginally bigger effect than 5 FU [20].
We detected no major difference between 5 fluorouracil and beta radiation. While our trial was
not powered to demonstrate equivalence of beta radiation and 5FU, our data provide no evi-
dence that beta-radiation is less effective than 5FU, which is reassuring given the considerable
supply chain and cost advantages of beta-radiation. The lack of evidence of a difference
between them is consistent with the conclusions of the Cochrane reviews of trabeculectomy
surgery and O’Donoghue et al who found that β radiation had a similar anti scarring effect as
5FU in their 1 year randomised trial [21]. Factors recognised to influence surgical success in
trabeculectomy surgery include type of glaucoma, number and type of IOP lowering drops and
conjunctival morphology. These factors were equally distributed between groups by the rando-
misation process.
A number of studies have reported on the outcomes of glaucoma filtration surgery in sub-
Saharan African patients (S2 Table) [18,22–34]. Reported IOP success rates for glaucoma sur-
gery at 1 year range from 46% to 91%. A consistent factor affecting outcome is duration of fol-
low-up. Looking at outcomes between 8–24 months post-operatively, the use of adjunctive
anti-scarring therapy seems to show some superiority. With no anti-scarring therapy success
in the region of 70–80% seems the norm whilst the use of anti-scarring therapy generally
increases this to 80–90%. Relatively little genetic variation has been reported amongst Bantu
ethnic groups [35] and post-operative IOPs in a South African study of trabeculectomy with
MMC for angle recession glaucoma [36] were comparable to the outcomes in an East African
study (16). It therefore appears reasonable to compare the results in this study with those we
found previously in South Africa (18). The South African study assessed cumulative failure. At
Table 6. Per and Postoperative complications.
Complications Intra operative Post operative
1 week n = 300 1 month n = 275 3 months n = 219 6 months n = 197  1 year n = 211
*Major 15 (5.0%)
**Minor 14 (4.6%)
Bleb leak 12 (3.9%) 1 (0.4%)
Corneal edema 115 (38%) 4 (1.5%) 2 (0.9%) 2 (1.0%) 1 (0.5%)
Shallow AC 6(1.9%) 2(0.7%)
Hyphema 5(1.7%)
Fibrinous AC reaction 7 (2.3%) 4(1.5%) 1 (0.5%) 1 (0.5%)
Hypopyon 1(0.3%)
RetainedSoft lens matter 3(1.0%)
Vitreous hemorrhage 1 (0.5%)
Hypotony*** 3(1.0%)
Malignant glaucoma 1 (0.5%)
Vitritis 1 (0.5%)
IOL capture 2 (0.7%)
*Conjunctival button hole, vitreous loss, excessive bleeding from Iridectomy site.
**Sub-Conjunctival haemorrhage, Posterior capsular tear, Recurrent Iris prolapse, Raised intra ocular pressure.
*** No choroidal detachments were seen.
doi:10.1371/journal.pone.0161674.t006
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one year the success rate was 95% in the beta-radiation group and 70% in the placebo group
using an IOP cut-off of21mmHg. On this basis, our finding of 75% success at one year sug-
gests that the addition of phacoemulsification to the procedure may reduce the success of tra-
beculectomy surgery to levels more aligned with trabeculectomy surgery without any anti-
scaring therapy. An interesting finding to note is that a majority of the time points in our study
recorded success in the region of 90% in each group. By 1 year of follow-up the cumulative risk
of “ever” failure estimated in the survival analysis substantially exceeds the “snapshot” risk of
failure at any given time point, highlighting the care that needs to be taken when comparing
cumulative risks with cross-sectional measures of success/failure. The only other report we
could find of phacotrabeculectomy surgery in an African context is our own case series from
CCBRT which indicated a cross-sectional success of 84% in those with 6 months or more fol-
low-up. This is similar to the cross-sectional measures of success seen in this trial. Interestingly,
although small, the prospective study by Ogata-Iwao et al had 73% cumulative success
(IOP21) at one year for phacotrabeculectomy with mitomycin C compared to 96% success in
patients with trabeculectomy alone.
Siriwardena et al compared anterior chamber reaction using flare readings (measured in
photons/millisecond) after trabeculectomy and phacoemulsification surgery. Initially similar
flare readings normalized to pre-operative levels in trabeculectomy eyes after 4 weeks but took
6 months to return to normal in phaco-emulsified eyes [37]. A reason for increased failure in
phacotrabeculectomy may well be prolongation of the post-operative inflammatory response.
Our patients remained on topical steroids for three months post-operatively; it may be that this
period should be prolonged.
It is evident from this study that phacotrabeculectomy improves vision in spite of advanced
glaucomatous damage. Our patients on average gained 3 acuity lines by 1 year of follow up. Of
note however the fact that the maximum gain was only attained 1 year post operatively.
Although this could be subject to bias as a result of differential loss to follow-up, this finding is
consistent with the report of Jin et al [38]. No patient experienced a long term decrease in acu-
ity as a result of the surgery. 5FU is well recognised as causing temporary epithelial change in
some patients (20) and this may explain the decrease in acuity in that group at day 7. Any sub-
sequent difference between the groups may be a chance finding.
This study highlights several critical points in the quest for a therapeutic strategy for the
glaucomas within an African context. Firstly, there is no evidence of a difference between the
use of 5FU and beta radiation as an anti-metabolite in phacotrabeculectomy surgery. Secondly
phacotrabeculectomy is a successful operation that improves vision as well as controlling IOP
in the majority of patients. The success of trabeculectomy in lowering IOP is reduced when
combined with phacoemulsification in comparison with trabeculectomy alone. This finding
has to be set against the possible need for subsequent cataract surgery in the presence of a func-
tioning trabeculectomy which represents a second trip and expense for the patient and results
in 10–61% failure of the trabeculectomy at one year post-cataract surgery[10]
We believe further work is required to delineate the outcomes and risks of other surgical
options however the results presented here represent a step forward in informing the debate.
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